4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results